iBio, Inc. - 8-K Filing

iBio updated its corporate presentation in September 2026 highlighting next-gen obesity therapies and near-term clinical milestones. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $IBIO

Read the full article at SEC EDGAR

More Regulatory news